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Summary
In anticipation of an interseasonal respiratory syncytial
virus (RSV) epidemic, a clinician-led reporting system was
rapidly established to capture RSV infections in Swiss
hospitals, starting in January 2021. Here, we present de-
tails of the reporting system and first results to June 2021.
An unusual epidemiology was observed with an intersea-
sonal surge of RSV infections associated with
COVID-19-related non-pharmacological interventions.
These data allowed real-time adjustment of RSV prophy-
laxis guidelines and consequently underscore the need
for and continuation of systematic nationwide RSV surveil-
lance.
Introduction
Respiratory syncytial virus (RSV) is a major cause of res-
piratory tract infection in children under 5 years of age
worldwide, with a substantial clinical burden [1, 2]. Before
the onset of the COVID-19 pandemic, typical seasonality
was reported for regions with temperate climates, with
RSV infections peaking during the autumn and winter sea-
sons [3]. However, since the onset of the COVID-19 pan-
demic, reports from Australia and the US, and more recent-
ly from other European countries and Israel, have provided
evidence of altered RSV epidemiology, with low activity
during the typical season and an interseasonal outbreak
[4–10]. Although RSV is not yet listed as a notifiable dis-
ease in the European Union [11, 12], the European Centre
for Disease Prevention and Control (ECDC) publishes da-
ta from several European countries [13] and urges system-
atic real-time reporting to provide data for relevant deci-
sion making on preventive measures [12]. In Switzerland,
no national real-time surveillance system for RSV has been
established to date. Here, we describe RSV EpiCH, a mul-
ticentre database managed from paediatric hospitals across
Switzerland that has continuously collected and dissem-
inated data on RSV infections in children since January
2021.
Network description, data capture and analy-
sis
Alerted by reports of exceptional RSV activity during the
summer 2020/21 in New South Wales, Australia [5], and
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first cases of RSV infections in Swiss centres, we contact-
ed 20 of 29 paediatric acute care hospitals in Switzerland
in April 2021. Members of the "Paediatric infectious dis-
ease group Switzerland" at each site were informed about
RSV EpiCH and were invited to provide their local data
to this central database on a weekly basis. No ethical con-
sent was required as only aggregated and anonymised data
were processed. The 20 participating centres include all 7
tertiary care hospitals (including all 5 paediatric university
hospitals), 10 of 13 secondary care regional hospitals, and
3 of 9 primary care local hospitals (table 1). Centres were
given individual access to a REDCap database and provid-
ed weekly aggregated numbers of children with a positive
RSV detection, divided into three age groups (infants, 1–2
years old, and older than 2 years), with no missing data
for these values. For most hospitals, we also captured the
number of total tests performed per week (not split into
age groups). The complete data processing workflow from
downloading the data from the REDCap database using the
REDCap application programming interface to generating
tables and graphics for public dissemination was coded in
R [14].
For each hospital, we recorded which patient populations
were generally tested (inpatient versus outpatient versus
both), the testing strategy (untargeted, i.e., all children with
fever or respiratory symptoms, versus targeted testing, i.e.,
only infants with bronchiolitis), and the type of test used
(table 1). We retrospectively collected data from January
2021.
RSV epidemiology in children in Switzerland
before and during the COVID-19 pandemic
Prior to the COVID-19 pandemic, most children with RSV
infections in Swiss hospitals were diagnosed between No-
vember and April, with peak infections occurring between
December and February [15] (fig. 1).
In contrast, during the 2020/2021 winter season, virtually
no RSV infections were observed in hospitals participating
in RSV EpiCH (n = 12, January and February 2021). How-
ever, RSV case numbers increased steadily from April
2021 onward, coinciding with a decline in SARS-CoV-2
case numbers and an associated relaxation of non-pharma-
cological interventions in Switzerland (fig. 2).
The large number of RSV infections detected in children
in May (337 cases) and June 2021 (425 cases) are well
outside the normal range for spring and summer months
in Switzerland (fig. 1). Interestingly, we observed regional
differences, with more cases detected in larger cities and
Western Switzerland affected earlier than the rest of
Switzerland (fig. 3).
Overall, 54% of cases were observed in infants, 24% in
children aged 1 to 2 years, and 23% in children older than
2 years (fig. 2).
Comparison with data from the USA, Aus-
tralia and Europe
An interseasonal increase in RSV infections has already
been reported for the autumn of 2020 in New South Wales,
Australia [5], and spring 2021 in New York, USA [4], co-
inciding with a local decline in COVID-19 case numbers
and a relaxation of non-pharmacological interventions .
Recently published data describe RSV activity delayed
by about 2–3 months in France and Iceland, whereas in
the Netherlands and the United Kingdom the onset of the
RSV epidemic was not visible until after calendar week
20, about 6 months late [6, 10]. It is noteworthy that in
France and Iceland only short or no school closures were
enforced. In contrast, longer school closures were imposed
in the Netherlands and the UK. As in France and Iceland,
Table 1:
Description of centres and testing modalities.
Abbr. Institution Type Testing strategy Targeted / untargeted Tests
used






AG Cantonal Hospital of Baden Regional hospital In- and outpatient Targeted PCR,
Antigen
BS University Children’s Hospital Basel Tertiary care hospital In- and outpatient Untargeted PCR
BE University Hospital Bern Tertiary care hospital Inpatient only Untargeted Antigen
BE Spitalzentrum Biel Regional hospital Inpatient only Untargeted PCR
FR Fribourg Hospital HFR Regional hospital Inpatient only Targeted PCR
GE Geneva University Hospital Tertiary care hospital Inpatient only Targeted Antigen
GR Cantonal Hospital of Graubünden Regional hospital Inpatient only Untargeted PCR
KSM Cantonal Hospital Münsterlingen Regional hospital Inpatient only Untargeted PCR
KSW Cantonal hospital of Winterthur Regional hospital Inpatient only Targeted PCR
LU Children’s Hospital Lucerne, Cantonal Hospital of Lucerne Tertiary care hospital Inpatient only Untargeted PCR
Targeted Antigen
NE Réseau hospitalier neuchâtelois Regional hospital Inpatient only Targeted PCR
SG Cantonal Hospital of St. Gallen Tertiary care hospital Inpatient only Targeted PCR
TI Istituto Pediatrico della Svizzera Italiana (Locarno, Bellinzona,
Lugano, Mendrisio), Ente Ospedaliero Cantonale
One Regional hospital,
two local hospitals
Inpatient only, occasionally outpatient Targeted PCR,
Antigen
VD Lausanne University Hospital Tertiary care hospital Inpatient only Targeted PCR
ZH University Children’s Hospital Zurich Tertiary care hospital Inpatient only Untargeted PCR
ZH Triemli Hospital Zurich Regional hospital In- and outpatient Targeted Antigen
PCR = polymerase chain reaction; Antigen = RSV antigen test
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schools and day-care centres in Switzerland were not
closed in the autumn of 2020 and winter of 2020/2021, and
children younger than 10–12 years (depending on the re-
gion) did not wear masks at school. This contrasts with
adolescents and adults, who had significant restrictions
and thus marked changes in their contacts, indicating an
important role of adolescents and adults as RSV reservoirs
and for the spread of RSV in a community (fig. 2). The
widespread implementation of non-pharmacological inter-
Figure 1: Comparison of RSV case numbers before and during COVID-19 pandemic in (A) Zurich and (B) Berne.
Figure 2: Weekly number of RSV infections in children in Swiss hospitals from 1 January to 4 July 2021, stratified by patient age. The black
horizontal bars on top of the plot indicate the main non-pharmaceutical interventions in Switzerland, with increasing bar height indicating
stronger restrictions: General recommendations 1. Public hygiene and social distancing >1.5 m (since 2 March 2020). Mandatory face masks
in public transport for persons older than 10–12 years old (depending on region, since 6 July 2020) and in publicly accessible indoor venues
(since 19 October 2020). Restrictions on private life; maximum number of people allowed to meet privately indoors 2. 30 persons (since 31
May 2021) 3. 15 persons (19 Apr to 30 May 2021) 4. 10 persons (29 Oct 2020 to 17 Jan 2021; 22 Mar to 18 Apr 2021) 5. 5 persons (18 Jan -
21 Mar 2021) Restrictions on public life 6. Closure of restaurants and bars (22 Dec 2020 to 30 May 2021) 7. Cultural venues closed (22 Dec
2020 to 18 Apr 2021) 8. Non-essential shops closed (18 Jan to 28 Feb 2021)
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ventions can be considered the main reason for the low
RSV transmission in the European winter [4, 5, 7].
Potential implication for future RSV epidemi-
ology
In a study published in December 2020, Baker et. al pre-
dicted altered RSV epidemiology after long periods of
non-pharmacological interventions, based on epidemiolog-
ical models using data from previous RSV seasons in
Texas and Florida [16]. In their analysis, an accumulation
of RSV-susceptible individuals after a "missed" RSV sea-
son may lead to an unusually high number of RSV infec-
tions in the subsequent season (2021/2022). However, the
impact of the interseasonal increase in RSV infections now
observed in some regions on future epidemiology remains
unclear.
Implications for palivizumab prophylaxis
Although several vaccines and antiviral therapies are in
active development, only palivizumab, a monoclonal an-
tibody against the RSV fusion protein, is currently avail-
able for prophylaxis in high-risk patients (e.g., infants with
bronchopulmonary dysplasia or congenital cyanotic heart
disease) [17]. Palivizumab is usually administered at
monthly intervals during the 5–6 months of the peak RSV
season. In some regions the recent changes in RSV epi-
demiology have meant that the prophylaxis administered
during the winter months of 2020/21 was of no clinical
benefit, which raises questions of whether and when addi-
tional doses of palivizumab should be offered to high-risk
patients [18]. Because the complete absence of the RSV
epidemic could not be predicted with certainty for the win-
ter of 2020/2021, high-risk patients in Switzerland contin-
ued to receive palivizumab prophylaxis for the usual 5–6
“RSV months” as reimbursed by insurance.
In preparation for a possible interseasonal RSV epidemic,
RSV EpiCH study members approached the authorities in
May 2021 and succeeded in having the usual 6-month lim-
it for reimbursements lifted. By calendar week 27, sev-
eral centres of the RSV EpiCH network had already rec-
ommended additional doses of palivizumab for at risk
patients.
To raise awareness of RSV amongst clinicians and support
primary care paediatricians in their decision to offer
palivizumab to patients, we reported our data in a weekly
newsletter of the Swiss Paediatric Society distributed to
over 3000 healthcare professionals in Switzerland. RSV
EpiCH data were also updated weekly on the society web-
site [19].
Conclusion
We report a shift in the usual RSV epidemiology in infants
and children in Switzerland in 2021, coinciding with a re-
laxation of non-pharmacological interventions due to the
Figure 3: Regional distribution of the weekly number of RSV infections in children in Switzerland from 1 January to 4 July 2021 (calendar
weeks 126). AG = Cantonal Hospital Aarau and Cantonal Hospital of Baden; BS = University Children’s Hospital Basel; BE = University Hospi-
tal Bern and Spitalzentrum Biel; FR = Fribourg Hospital HFR; GE = Geneva University Hospital; GR = Cantonal Hospital of Graubünden; KSW
+ KSM = Cantonal Hospital of Winterthur and Cantonal Hospital Münsterlingen; LU = Lucerne Children’s Hospital, Cantonal Hospital of
Lucerne; NE = Réseau hospitalier neuchâtelois; SG = Cantonal Hospital of St Gallen; TI = Istituto Pediatrico della Svizzera Italiana (Locarno,
Bellinzona, Lugano, Mendrisio), Ente Ospedaliero Cantonale; VD = Lausanne University Hospital; ZH = University Children’s hospital Zurich
and Triemli Hospital Zurich.
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COVID-19 pandemic. A rapidly established clinician-led
initiative to collect information on RSV cases in Swiss
hospitals proved successful in demonstrating regional and
national dynamics of RSV infection in Switzerland. Al-
though regional differences may be partly explained by
differences in awareness and testing strategies among par-
ticipating hospitals, RSV EpiCH data have been instru-
mental for communication with authorities and insurers,
may prove useful in raising awareness of RSV infection,
and provide early information to guide national policy on
RSV prevention and distribution of healthcare resources in
paediatric hospitals. The long-term sustainability of such a
clinician-led initiative requires additional support, and we
are seeking discussions with the relevant authorities with
the aim of introducing mandatory reporting of RSV detec-
tion by all laboratories in Switzerland.
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